News
PRQR
1.100
-4.35%
-0.050
Weekly Report: what happened at PRQR last week (1109-1113)?
Weekly Report · 2d ago
ProQR Therapeutics price target lowered to $7 from $8 at BofA
TipRanks · 5d ago
ProQR Therapeutics N.V. Reports Third Quarter 2026 Operating and Financial Results
NASDAQ · 5d ago
ProQR Therapeutics N.V. Announces Third Quarter 2026 Operating and Financial Results
NASDAQ · 5d ago
Biotech Stocks Rally: ADXN Soars 71%, ENGN Jumps 26%, NTHI Gains 12%, PRQR Rises 10%
NASDAQ · 6d ago
ProQR Announces Third Quarter 2026 Operating and Financial Results
TipRanks · 6d ago
ProQR Announces Third-Quarter 2026 Operating and Financial Results
TipRanks · 6d ago
ProQR Therapeutics Q3 Sales Increase
NASDAQ · 6d ago
ProQR Therapeutics reports Q3 EPS (EUR 0.09) vs. (EUR 0.10) last year
TipRanks · 6d ago
Weekly Report: what happened at PRQR last week (1102-1106)?
Weekly Report · 11/09 09:02
Weekly Report: what happened at PRQR last week (1026-1030)?
Weekly Report · 11/02 09:02
ProQR Therapeutics N.V. to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
NASDAQ · 10/28 17:59
ProQR to Showcase AX-0810 and AX-0811 RNA Editing Data at Late-2026 Conferences
TipRanks · 10/28 12:28
ProQR Therapeutics To Present Data On Its AX-0810, AX-0811 At The Liver Meeting 2026, Nature Conferences RNA
Benzinga · 10/28 12:01
Weekly Report: what happened at PRQR last week (1019-1023)?
Weekly Report · 10/26 09:02
Weekly Report: what happened at PRQR last week (1012-1016)?
Weekly Report · 10/19 09:02
ProQR Therapeutics management to meet with Oppenheimer
TipRanks · 10/14 19:50
ProQR Therapeutics management to meet with Oppenheimer
TipRanks · 10/12 20:10
Weekly Report: what happened at PRQR last week (1005-1009)?
Weekly Report · 10/12 09:02
Weekly Report: what happened at PRQR last week (0928-1002)?
Weekly Report · 10/05 09:02
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).